Australia Small Molecule Cdmo Market Size & Outlook
Related Markets
Australia small molecule cdmo market highlights
- The Australia small molecule cdmo market generated a revenue of USD 734.4 million in 2024 and is expected to reach USD 1,352.2 million by 2033.
- The Australia market is expected to grow at a CAGR of 7.2% from 2025 to 2033.
- In terms of segment, active pharmaceutical ingredients (api) was the largest revenue generating product in 2024.
- Active Pharmaceutical Ingredients (API) is the most lucrative product segment registering the fastest growth during the forecast period.
Small molecule cdmo market data book summary
| Market revenue in 2024 | USD 734.4 million |
| Market revenue in 2033 | USD 1,352.2 million |
| Growth rate | 7.2% (CAGR from 2025 to 2033) |
| Largest segment | Active pharmaceutical ingredients (api) |
| Fastest growing segment | Active Pharmaceutical Ingredients (API) |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Active Pharmaceutical Ingredients (API), Finished Drug Products |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Eurofins Scientific SE, Aurigene Pharmaceutical Services |
Other key industry trends
- In terms of revenue, Australia accounted for 1.0% of the global small molecule cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China small molecule cdmo market is projected to lead the regional market in terms of revenue in 2033.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 8,042.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Small Molecule CDMO Market Scope
Small Molecule CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Aurigene Pharmaceutical Services | View profile | 501-1000 | Bangalore, Karnataka, India, Asia | https://www.aurigeneservices.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Australia small molecule cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule cdmo market will help companies and investors design strategic landscapes.
Active pharmaceutical ingredients (api) was the largest segment with a revenue share of 65.65% in 2024. Horizon Databook has segmented the Australia small molecule cdmo market based on active pharmaceutical ingredients (api), finished drug products covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Australia small molecule cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia small molecule cdmo market databook
-
Our clientele includes a mix of small molecule cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia small molecule cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Australia small molecule cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Australia small molecule cdmo market report size, by product, 2021-2033 (US$M)
Australia Small Molecule CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
